Results 61 to 70 of about 6,342 (159)
Journal of Applied Toxicology, Volume 45, Issue 12, Page 2641-2653, December 2025.ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu +7 more
wiley +1 more source
CYP2D6-polymorphism and effect of adjuvant tamoxifen in breast cancer patients
, 2023 Adjuvant tamoxifen at the standard dose of 20 mg daily for five to ten years reduces the risk for relapse and mortality in hormone sensitive breast cancer. The effect however varies and no early marker of poor response is yet available.
Linda Thorén (18661456)
core
, 1997 Hepatic oxidation is a major drug metabolising process and is carried out by the cytochrome P-450 monooxygenase system. This system consists of a variety of isoenzymes among which the cytochromes 1A2, 2C8, 2C9/10, 2C19, 2D6, 2E1 and 3A4 are involved in ...
Touw, D J; id_orcid
core +1 more source
The effects of pharmacogenetics on pharmacokinetics of artemisinin-based combinations in malaria patients [PDF]
, 2009 Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become life-threatening, leading to an estimated 900’000 annual deaths globally. Key
Hodel, Eva Maria
core +1 more source
, 2017 Functional cross-talk among human drug-metabolizing cytochrome P450 through their association is a topic of emerging importance. Here, we studied the interactions of human CYP2D6, a major metabolizer of psychoactive drugs, with one of the most prevalent ...
Thomas H. Rushmore +4 more
core +1 more source
Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics [PDF]
, 2018 Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters ...
Deirdre P. Cronin-Fenton +3 more
core +1 more source
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? [PDF]
, 2010 BACKGROUND: In inflammation and infection, cytochrome P450 (CYP) enzyme activities are down-regulated. Information on possible discrepancies in activities of CYP enzymes and drug transporters between HIV-infected patients and healthy people is limited ...
Frank, D +21 more
core +1 more source
Drug Design, Development and Therapy, 2018 Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of ...
Sychev DA +9 more
doaj
Human genetic variation with implications for healthcare in Ethiopian populations
, 2010 Cytochrome P450 1A2 metabolizes a wide range of therapeutic drugs, including several used to treat diseases common in sub-Saharan Africa. Variation in the gene (CYP1A2) has been reported to be associated with differential efficacy of therapeutic drugs ...
Browning, S.L.
core
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo
, 2015 The cytochrome P450-dependent mono-oxygenase system is responsible for the metabolism and disposition of chemopreventive agents, chemical toxins and carcinogens, and >80% of therapeutic drugs.
Henderson, Colin J. +4 more
core +1 more source